Integrative bioinformatics and experimental validation reveal quercetin as a potential multi-target therapeutic agent
Longfei Zeng1, Gang Zhu1, Shaozhen Tang1
1Department of General Surgery, Second Ward, Luzhou People's Hospital, Luzhou, China.
Abstract:
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer worldwide, with increasing incidence and mortality rates. Although several targeted therapies are currently available, the therapeutic outcomes remain unsatisfactory due to the high heterogeneity and drug resistance of HCC. Therefore, novel molecular mechanisms and therapeutic strategies urgently need to be explored. In this study, we obtained the GSE39791 dataset from the GEO database and identified 1,186 differentially expressed genes (DEGs). Weighted gene co-expression network analysis (WGCNA) was conducted to obtain 776 key module genes, which were intersected with 11,671 HCC-related genes from the GeneCards database, resulting in 226 candidate genes. A protein-protein interaction (PPI) network was constructed using the STRING database, and the top 20 hub genes were identified using the MNC algorithm in Cytoscape. Among these, the five most significant hub genes-RFC4, TOP2A, AURKA, HSP90AA1, and MCM4-were selected for further analysis. KEGG enrichment analysis was performed to explore their functional pathways. Potential therapeutic agents were predicted using the CMap database, and molecular docking was conducted via AutoDock Vina. To validate the computational predictions, a quercetin intervention model was established. The optimal dose was determined through CCK-8 assays in HepG2 cells, and the expression of the five hub genes was examined in normal liver cells (LO2), HepG2 cells, and HepG2 cells treated with quercetin using RT-qPCR. The five hub genes-RFC4, TOP2A, AURKA, HSP90AA1, and MCM4-were significantly overexpressed in both HCC tissues and cell lines. Enrichment analysis revealed that these genes were mainly involved in cancer-related pathways, including the cell cycle, p53 signaling pathway, and FoxO signaling pathway. Drug prediction analysis showed that quercetin exhibited a negative regulatory pattern with respect to HCC and displayed binding energies below - 5 kcal/mol with all five hub proteins. CCK-8 assays confirmed the dose-dependent inhibitory effect of quercetin on HepG2 cell viability. RT-qPCR results demonstrated that quercetin significantly downregulated the expression of the five hub genes, consistent with the bioinformatics predictions. This study integrated multi-omics analysis and experimental validation to identify five core genes closely associated with HCC and suggested that quercetin may exert anti-HCC effects partly associated with the regulation of these genes. Our findings offer new insights into the molecular mechanisms of HCC and provide a promising strategy for the development of targeted therapeutics.
Supplementary Information:
The online version contains supplementary material available at 10.1007/s10616-026-00993-x.
Insights
Hepatocellular carcinoma (HCC) research identified five key genes (RFC4, TOP2A, AURKA, HSP90AA1, MCM4) driving liver cancer. The natural compound quercetin shows promise in downregulating these genes and inhibiting HCC progression.
Area of Science:
- Oncology
- Bioinformatics
- Molecular Biology
Background:
- Hepatocellular carcinoma (HCC) incidence and mortality are rising globally.
- Current targeted therapies for HCC show limited efficacy due to drug resistance and tumor heterogeneity.
- Novel molecular targets and therapeutic strategies are crucial for improving HCC treatment outcomes.
Purpose of the Study:
- To identify key molecular mechanisms and potential therapeutic targets for Hepatocellular carcinoma (HCC).
- To investigate the therapeutic potential of quercetin in HCC by targeting identified hub genes.
- To integrate multi-omics data analysis with experimental validation for HCC research.
Main Methods:
- Differential gene expression analysis of the GSE39791 dataset.
- Weighted gene co-expression network analysis (WGCNA) to identify key modules.
- Protein-protein interaction (PPI) network construction and hub gene identification using STRING and Cytoscape.
- KEGG pathway enrichment analysis.
- Drug prediction using the CMap database and molecular docking with AutoDock Vina.
- Experimental validation using CCK-8 assays and RT-qPCR in HepG2 and LO2 cell lines.
Main Results:
- Identified 226 candidate genes, with RFC4, TOP2A, AURKA, HSP90AA1, and MCM4 selected as the top five hub genes.
- These five hub genes were significantly overexpressed in HCC and involved in cell cycle and cancer-related signaling pathways.
- Quercetin demonstrated a dose-dependent inhibitory effect on HepG2 cell viability and downregulated the expression of the five hub genes.
- Molecular docking confirmed binding affinities between quercetin and the five hub proteins.
Conclusions:
- RFC4, TOP2A, AURKA, HSP90AA1, and MCM4 are critical genes associated with Hepatocellular carcinoma (HCC) progression.
- Quercetin exhibits potential anti-HCC effects, partly mediated by the downregulation of these five hub genes.
- This study provides a foundation for developing novel targeted therapies for HCC.
More Related Videos
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
12:24A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
Published on: September 30, 2021
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
